📰 Clinical Proof News
Clinical Proof News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Clinical Proof. Real-time updates on events, politics, business and more.
April 30, 2024
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATIONS NO. 596/2014 AS IT FORMS...
April 30, 2024
Avacta appoints new Chief Executive Officer Christina Coughlin, MD PhD Clinical proof-of-concept demonstrated for Avactas lead programme AVA6000 and proof-of-mechanism for the...
June 28, 2023
Medical Director, Oncology - Early Development in Full time, Director, Biomedicine with Adveritas - F. Hoffmann la Roche. Apply Today.
May 17, 2023
Second patient scheduled for implantation with NVD-003 in June 2023 Pivotal trial is expected to begin in the second half of 2024* Novadip Biosciences SA ("Novadip" or "the Company"), a clinical-stage
March 16, 2023
In a small phase 2 trial, subcutaneous exenatide led to a significant reduction in intracranial pressure and number of monthly headaches in patients with IIH.
January 9, 2023
In most people's minds, the first thing that comes to mind when they encounter the term "diabetes" is the sugar that is responsible for the disease. Having
January 21, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation. reMYND extends Series B funding to EUR 24 million reMYNDJanuary 21, 2021 GMT reMYND extends Series B funding to EUR 24 million Financing enables advancement of key programs in Alzheimer’s and Diabetes through Clinical Proof of Concept in 2022 Additional EUR 12 million raised Leuven Belgium, 21 January 2021: reMYND NV, a clinical stage company developing innovative treatments for Alzheimer’s, diabe...